CN103566355A - Composite lotus root starch preparation - Google Patents
Composite lotus root starch preparation Download PDFInfo
- Publication number
- CN103566355A CN103566355A CN201310548590.7A CN201310548590A CN103566355A CN 103566355 A CN103566355 A CN 103566355A CN 201310548590 A CN201310548590 A CN 201310548590A CN 103566355 A CN103566355 A CN 103566355A
- Authority
- CN
- China
- Prior art keywords
- osteoporosis
- lotus root
- root starch
- bone
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composite lotus root starch preparation which is mainly prepared from lotus root starch, walnut powder and casein phosphopeptides.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of compound Amylum Nelumbinis Rhizomatis preparation.
Background technology
Osteoporosis is a kind of commonly encountered diseases and frequently-occurring disease, and it is seriously threatening middle-aged and elderly people, and especially postmenopausal women is healthy.The complication such as the fracture being caused by osteoporosis, have caused great misery to patient, return society and family and have brought heavy economy and living burden.According to reports, the probability that the osteoporotic women of generation occurred hip, spinal column, forearm or proximal humeral fracture in 10 years later in 50 years old is up to 45%; Be greater than 65 years old old man when unconscious falling, have 87% can cause osteoporotic fracture.China old people's absolute quantity accounts for No. 1 in the world, and along with the growth of growth in the living standard and population life, the aged sharply increases, and therefore, the diagnosis of osteoporosis and control thereof just seem very important.
Osteoporosis can be divided into three major types, and a class is primary osteoporosis, is a kind of physiological degeneration that must occur with advancing age.Equations of The Second Kind is secondary osteoporosis, and it is the osteoporosis of being brought out by some factors such as Other diseases or medicines.The 3rd class is idiopathic osteoporosis disease, is more common in teenager or the adult of 8～14 years old, mostly has family's heredity medical history, and women is more than male.The osteoporosis that gravid woman and women breast-feeding their children occur also can be listed idiopathic osteoporosis in, to cause people's attention.
The main clinical manifestation of osteoporosis and sign are: pain, height shortening, hunchback, fragility fractures and Respiratory Disturbances etc.
1) pain
Pain is the common sympton of osteoporosis, and its reason is mainly that bone resorption increases because bone conversion is high.In bone resorption process, bone trabecular destruction, disappearance, the destruction of subperiosteum cortical bone etc. all can cause general osteodynia, wherein common with lumbago and backache.Another causes that the major reason of pain is fracture.
2) height shortening, hunchback
In silent middle height, shortening or bow-backed, is one of important clinical sign occurring continue lumbago and backache after, and 5-20 centimetre of height shortening is not sometimes etc.
3) fragility fractures
In osteoporosis, skeleton fracture threshold reduces significantly, thereby just easily fractured by slight external force.
4) Respiratory Disturbances
Breast, compression fracture of lumbar vertebra due to serious osteoporosis, usually cause kyphosis, chest deformity, and thoracic cavity capacity obviously declines, and sometimes can cause the changes of function of a plurality of internal organs, and wherein the performance of respiratory system is particularly outstanding.
The final purpose of Prevention and Treatment of Osteoporosis is to reduce the generation of fracture.Adopt clinically and delay and reduce bone loss, strive for recapturing bone amount, increase bone strength and reach this object.The treatment measure of osteoporosis is divided into basic measure and two aspects of Drug therapy.In the measure of basis, bone health supplement are mainly calcium preparation and vitamin D; Drug therapy mainly comprises anti-bone resorption medicine, short bone formation medicine and other drug.
Summary of the invention
The object of the present invention is to provide a kind of compound Amylum Nelumbinis Rhizomatis preparation.
For achieving the above object, the present invention adopts the component of following weight ratio: 45 parts of Amylum Nelumbinis Rhizomatis, 45 parts of walnut powders, 10 parts of phosphopeptide caseinates.
Preparation of the present invention, basic upper at mentioned component, directly or again adds suitable edible or pharmaceutic adjuvant, can make the dosage forms such as solid granules.
The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
The specific embodiment
Embodiment 1: a kind of compound Amylum Nelumbinis Rhizomatis preparation, its raw material and weight portion are: 45 parts of Amylum Nelumbinis Rhizomatis, 45 parts of walnut powders, 10 parts of phosphopeptide caseinates.Add adjuvant, make the dosage forms such as solid granules.
Embodiment 2: effect Journal of Sex Research
The product that inventor makes the specific embodiment of mentioning in content of the present invention, takes effect comparative study with calcium preparation, below enumerates one group of experimental data wherein.
30 male SD rats are divided into 3 groups by body weight homeostatic principle: low calcium matched group, calcium carbonate control group and of the present invention group, each is organized rat ad lib and specially joins accordingly feedstuff.Rat is fed 13 weeks continuously, and after last administration 24 hours, to put to death, separated left side femur, removes skin and flesh, measures the bone density of left side femur.
The impact of the present invention on rat bone density
| Group | Number of animals (only) | Femur mid point bone density (g/cm 2) |
| Low calcium matched group | 10 | 0.102±0.009 |
| Calcium carbonate control group | 10 | 0.109±0.007* |
| Of the present invention group | 10 | 0.112±0.009* |
With the comparison of low calcium matched group, * P<0.05
Result demonstration, in bone density experiment, with the comparison of low calcium matched group, of the present invention group of rat femur quality, calcium content of bone and femur mid point bone density all significantly increase, and show that the present invention has inhibitory action to osteoporosis.
Claims (1)
1. a compound Amylum Nelumbinis Rhizomatis preparation, is characterized in that, comprises the component of following weight ratio: 45 parts of Amylum Nelumbinis Rhizomatis, 45 parts of walnut powders, 10 parts of phosphopeptide caseinates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310548590.7A CN103566355A (en) | 2013-11-07 | 2013-11-07 | Composite lotus root starch preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310548590.7A CN103566355A (en) | 2013-11-07 | 2013-11-07 | Composite lotus root starch preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103566355A true CN103566355A (en) | 2014-02-12 |
Family
ID=50039636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310548590.7A Pending CN103566355A (en) | 2013-11-07 | 2013-11-07 | Composite lotus root starch preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103566355A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049157A (en) * | 2007-05-21 | 2007-10-10 | 北京东方兴企食品工业技术有限公司 | Functional health food for preventing osteoporosis |
| CN103127375A (en) * | 2012-12-20 | 2013-06-05 | 刘登富 | Chinese materia medica preparation for treating osteoporosis |
| CN103599186A (en) * | 2013-11-06 | 2014-02-26 | 苏州冉新生物技术有限公司 | Compound lotus root starch preparation |
-
2013
- 2013-11-07 CN CN201310548590.7A patent/CN103566355A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049157A (en) * | 2007-05-21 | 2007-10-10 | 北京东方兴企食品工业技术有限公司 | Functional health food for preventing osteoporosis |
| CN103127375A (en) * | 2012-12-20 | 2013-06-05 | 刘登富 | Chinese materia medica preparation for treating osteoporosis |
| CN103599186A (en) * | 2013-11-06 | 2014-02-26 | 苏州冉新生物技术有限公司 | Compound lotus root starch preparation |
Non-Patent Citations (1)
| Title |
|---|
| 余丽: "骨质疏松有良方，莲藕红枣牛骨汤", 《家庭医药》, no. 1, 1 January 2007 (2007-01-01), pages 68 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| CN102657842A (en) | Medicinal composition with function of increasing bone density and application thereof | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN106880839B (en) | Deer bone tablet and preparation method thereof | |
| CN105124583A (en) | Health-care food capable of enhancing bone mineral density and preparation method thereof | |
| CN103565830A (en) | Composite calcium preparation | |
| CN103565827A (en) | Resveratrol-containing tablets | |
| CN101607013A (en) | A kind of Chinese medicine bone-knitting capsule and preparation method | |
| CN103610740A (en) | Calcium chelate | |
| CN103599186A (en) | Compound lotus root starch preparation | |
| CN103566355A (en) | Composite lotus root starch preparation | |
| CN105595327A (en) | Special calcium citrate preparation for astronauts | |
| CN103610755A (en) | Granules for treating osteoporosis | |
| CN103565930A (en) | Granule for increasing bone density | |
| CN103599175A (en) | Granules for increasing bone density | |
| CN103599177A (en) | Composition for enhancing bone density | |
| CN103599174A (en) | Composition for improving bone mineral density | |
| CN103735613A (en) | Preparation for increasing bone mineral density | |
| CN103585264A (en) | Preparation capable of increasing bone mineral density | |
| CN103623048A (en) | Preparation containing pueraria isoflavones | |
| CN103599176A (en) | Composition for enhancing bone density | |
| CN103598579A (en) | Health-care food containing soy isoflavone | |
| CN103599524A (en) | Compound walnut powder solid preparation | |
| CN103599521A (en) | Vitamin D complex granules | |
| CN103611152A (en) | Compound vitamin D electuary |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140212 |